Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Baudax Bio, Inc. (BXRX)
|
Add to portfolio |
|
|
|
| Price: |
$0.24
| | Metrics |
| OS: |
6.97
|
M
| |
|
|
| Market cap: |
$1.69
|
M
| |
|
|
|
Net cash:
|
$1.42
|
M
| |
$0.20
|
per share
|
|
EV:
|
$269.1
|
k
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($55.4)
|
M
| |
|
|
|
EBIT
|
($52.9)
|
M
| |
|
|
| EPS |
($35.04)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 1.3 | 1.1 | 0.5 | 47.1 | 0.0 |
| Revenue growth | 17.5% | 119.1% | -99.0% | | |
| Cost of goods sold | 58.1 | 20.1 | 75.3 | 32.5 | 0.0 |
| Gross profit | -56.8 | -19.0 | -74.8 | 14.6 | 0.0 |
| Gross margin | -4477.0% | -1759.8% | -15169.6% | 30.9% | |
| Selling, general and administrative | 0.0 | 0.0 | 0.0 | 27.0 | |
| Research and development | | | | 20.1 | 35.6 |
| General and administrative | 0.0 | 0.0 | 0.0 | | 29.5 |
| EBITA | -58.8 | -18.0 | -57.2 | -32.5 | -73.5 |
| EBITA margin | -4632.5% | -1668.0% | -11597.4% | -69.1% | |
| Amortization of intangibles | 2.0 | 2.6 | 2.1 | | |
| EBIT | -60.8 | -20.6 | -59.3 | -32.5 | -73.5 |
| EBIT margin | -4789.9% | -1906.5% | -12032.7% | -69.1% | |
| Pre-tax income | -58.8 | -19.8 | -76.1 | -32.6 | -73.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -58.8 | -19.8 | -76.1 | -32.6 | -73.7 |
| Net margin | -4633.2% | -1830.5% | -15436.1% | -69.2% | |
| |
| Diluted EPS | ($177.30) | ($361.16) | ($142.87) | ($3.48) | ($7.88) |
| Shares outstanding (diluted) | 0.3 | 0.1 | 0.5 | 9.4 | 9.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|